Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II trial of escalating dose of yttrium-90-labeled anti-CD20 monoclonal antibody [ibritumomab tiuxetan Y 90] in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.

Next Previous
X
Search
Trial Profile

A phase I/II trial of escalating dose of yttrium-90-labeled anti-CD20 monoclonal antibody [ibritumomab tiuxetan Y 90] in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide; Etoposide; Ibritumomab tiuxetan
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 18 Jun 2021 Biomarkers information updated
    • 17 Dec 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 26 Nov 2012 Planned end date changed from 1 Oct 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top